Jeil Pharm Cash Flow-to-Debt Ratio
Jeil Pharm cash flow-to-debt ratio. Jeil Pharm (002620) has a Cash Flow-to-Debt Ratio of -0.01x as of June 2026, meaning its operating cash flow of ₩-4.71 Billion could theoretically repay 0% of its total liabilities (₩421.10 Billion) in one year. Check Jeil Pharm cash earnings quality to evaluate the quality of earnings relative to operating cash generation.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Cash Flow-to-Debt Ratio of Jeil Pharm (2011–2025)
Cash flow-to-debt ratio of Jeil Pharm from 2011 to 2025. Historical debt coverage capacity for Jeil Pharm across 13 annual periods. Check 002620 capex plus investments ratio to assess the company's total reinvestment commitment from operating cash flow.
Jeil Pharm Cash Flow-to-Debt Ratio by Year (2011–2025)
Jeil Pharm cash flow-to-debt ratio by year from 2011 to 2025. Year-by-year debt coverage analysis for Jeil Pharm. For the full cash flow conversion analysis, see Jeil Pharm (002620) cash conversion ratio.
| Year | CF-to-Debt Ratio | Operating CF (KRW) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | 0.00x | ₩390.26 Million | ₩407.55 Billion | ▼ -90.4% |
| 2024 | 0.01x | ₩4.54 Billion | ₩453.04 Billion | ▲ +208.5% |
| 2023 | -0.01x | ₩-4.42 Billion | ₩477.81 Billion | ▲ +80.2% |
| 2022 | -0.05x | ₩-20.80 Billion | ₩445.88 Billion | ▼ -236.5% |
| 2021 | 0.03x | ₩13.40 Billion | ₩392.11 Billion | ▲ +156.0% |
| 2020 | -0.06x | ₩-23.67 Billion | ₩388.11 Billion | ▼ -187.9% |
| 2019 | 0.07x | ₩25.22 Billion | ₩363.44 Billion | ▲ +768.0% |
| 2018 | -0.01x | ₩-3.43 Billion | ₩330.51 Billion | ▼ -104.8% |
| 2017 | 0.22x | ₩5.92 Billion | ₩27.15 Billion | ▲ +360.9% |
| 2016 | 0.05x | ₩11.36 Billion | ₩239.91 Billion | ▲ +251.6% |
| 2015 | 0.01x | ₩2.74 Billion | ₩203.78 Billion | ▲ +151.0% |
| 2012 | -0.03x | ₩-3.94 Billion | ₩149.36 Billion | ▼ -117.1% |
| 2011 | 0.15x | ₩23.63 Billion | ₩152.74 Billion | — |